﻿<?xml version="1.0" encoding="utf-8"?><!--RSS Genrated: Thu, 16 Apr 2026 01:54:10 GMT--><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:ev="http://purl.org/rss/1.0/modules/event/"><channel><title>American Pharmacists Association</title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/November-2023/rss/1531</link><atom:link href="http://www.pharmacist.com/Publications/Pharmacy-Today/November-2023/rss/1531" rel="self" type="application/rss+xml" /><description>RSS document</description><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[New and Approved]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/new-and-approved-1</link><description><![CDATA[  New drugs  

 MOTIXAFORTIDE 

 (Aphexda—BioLineRx) 

  Drug class:  Aphexda is a hematopoietic stem cell mobilizer. 

  Indication:  Aphexda is indicated in combination with filgrastim to ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/new-and-approved-1</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1720]]></dc:identifier></item><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[Pharmacists on the ground after Maui wildfires provide biggest medical need: medications]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/pharmacists-on-the-ground-after-maui-wildfires-provide-biggest-medical-need-medications</link><description><![CDATA[   

  Loren Bonner  

 After deadly wildfires ripped through Lahaina, located on the western edge of Maui, pharmacists quickly mobilized to get displaced residents their medications. 

 The ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/pharmacists-on-the-ground-after-maui-wildfires-provide-biggest-medical-need-medications</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1714]]></dc:identifier></item><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[Updated chronic coronary disease guidelines factor in new drug therapies]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/updated-chronic-coronary-disease-guidelines-factor-in-new-drug-therapies</link><description><![CDATA[   

  Loren Bonner  

 Taking into consideration specific recommendations on several new classes of medications as well as placing an emphasis on social determinants of health, the American ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/updated-chronic-coronary-disease-guidelines-factor-in-new-drug-therapies</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1715]]></dc:identifier></item><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[FDA approves first oral medication for postpartum depression]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/fda-approves-first-oral-medication-for-postpartum-depression</link><description><![CDATA[   

  Sonya Collins  

 In August 2023, FDA approved zuranolone (Zurzuvae), the first oral medication for postpartum depression. Until now, the only treatment specifically for postpartum ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/fda-approves-first-oral-medication-for-postpartum-depression</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1716]]></dc:identifier></item><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[Potential changes coming for nonprescription CBD products]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/potential-changes-coming-for-nonprescription-cbd-products</link><description><![CDATA[   

  Ariel L. Clark, PharmD  

 Over a decade has passed since the first states, Colorado and Washington, legalized cannabis for recreational use. Another 5 years have gone by since the Farm ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/potential-changes-coming-for-nonprescription-cbd-products</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1717]]></dc:identifier></item><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[Psyllium husk and weight loss]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/psyllium-husk-and-weight-loss</link><description><![CDATA[   

  Mickie Cathers  

 Weight loss is big business, and the popularity of Ozempic, the FDA-approved prescription T2D drug, was boosted by those using it off-label for weight loss. Called “the ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/psyllium-husk-and-weight-loss</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1718]]></dc:identifier></item><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[Phenylephrine: The story of  an ineffective nasal decongestant]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/phenylephrine-the-story-of-an-ineffective-nasal-decongestant</link><description><![CDATA[   

  Mary Warner  

 On September 12, 2023, the FDA Nonprescription Drugs Advisory Committee unanimously agreed that oral phenylephrine is ineffective, setting the stage for FDA to require its ...]]></description><pubDate>Tue, 07 Nov 2023 17:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/phenylephrine-the-story-of-an-ineffective-nasal-decongestant</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-1719]]></dc:identifier></item></channel></rss>